Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab
National Cancer Institute (NCI)
National Cancer Institute (NCI)
H. Lee Moffitt Cancer Center and Research Institute
UNC Lineberger Comprehensive Cancer Center
SWOG Cancer Research Network
National Cancer Institute (NCI)
Yale University
Radiation Therapy Oncology Group
Bristol-Myers Squibb
Merck Sharp & Dohme LLC
Incyte Corporation
Sanofi
GERCOR - Multidisciplinary Oncology Cooperative Group
Merck Sharp & Dohme LLC
Nektar Therapeutics
AIDS Malignancy Consortium
Menarini Group
NuCana plc
HiberCell, Inc.
Washington University School of Medicine
Merck Sharp & Dohme LLC
University of Arizona
GlaxoSmithKline
University of Cincinnati
The University of Texas Health Science Center at San Antonio
Pierre Fabre Medicament
Stanford University
Washington University School of Medicine
Pfizer
Rutgers, The State University of New Jersey
Pharmacyclics LLC.
Sumitomo Pharma America, Inc.
Bristol-Myers Squibb
Pfizer
Merck Sharp & Dohme LLC
Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group
University of Wisconsin, Madison
Roswell Park Cancer Institute
Bristol-Myers Squibb
Amgen
Radiation Therapy Oncology Group
Radiation Therapy Oncology Group
Radiation Therapy Oncology Group
Merck KGaA, Darmstadt, Germany
University of Texas Southwestern Medical Center
Memorial Sloan Kettering Cancer Center